| Name | Title | Contact Details |
|---|---|---|
Meina Liang |
Chief Technology Officer | Profile |
Pharmaceutical Specialties Inc is a Bogart, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Fundamentally we exist for one reason: To be the trusted solution for our clients as they strive to build a better working world and improve the human experience. We are 550+ global experts that bring top-tier expertise to every stage of a project, from creating comprehensive, detailed project plans to eliminating that last punch list item and beyond, into rigorous asset management, reliability, and sustainability activities. We are your choice regardless of your location. We can support you in the US, Singapore, China, Australia, Europe, Korea, Malaysia, Vietnam and beyond. Philosophically and practically, we believe that quality, cost, and schedule can be mutually reinforcing – trade-offs are not necessary. Short-changing the focus on quality usually means problems down the road – problems that can cost money and delay the schedule. But if quality is built in from the start, then both project delivery and operational efficiency can be achieved with a much higher degree of assurance. When your project requires planned, managed, and documented high quality to exacting global standards. When you need high-performance teams on mission-critical projects. When your project is complex, high-visibility, and carries significant risk. We can help you meet a higher standard.
Maitri Medicinals cultivates, produces and dispenses quality medical marijuana products to patients in Pittsburgh and Uniontown Pennsylvania who suffer from qualifying medical conditions and diseases.
TABUK Pharmaceuticals is a Overland Park, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.